EUVIMEDEUVIMED entdecken
Crossref

Targeting CD47 Enhanced the Antitumor Immunity of PD-L1 Blockade in B-Cell Lymphoma

Yanyang Nan, Xuyao Zhang, Shaofei Wang, Caili Xu, Yichen Wang, Lei Han, Jingyun Luan, Xiaozhi Hu, Wei Chen, Zhonglian Cao, Zeguo Zhu, Xian Zeng und 4 weitere

Immunotherapy · 2023

DOI: 10.2217/imt-2022-0087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy, 2023. Verfasst von Yanyang Nan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, 2012…. Hauptthemen laut MEDLINE: Lymphoma, B-Cell, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Scientific and Innovative Action Plan of Shanghai, National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Only a subset of B-cell lymphoma (BCL) patients can benefit from immune checkpoint inhibitors targeting PD-1/PD-L1. Materials & methods: In the A20 model, SIRPα-Fc and anti-PD-L1 were employed to target CD47 and PD-L1 simultaneously. Flow cytometry, immunofluorescence and quantitative polymerase chain reaction were used to unravel the potential mechanisms.

Results

Simultaneously targeting CD47 and PD-L1 activated CD8+ T cells with an increased release of effector molecules. Furthermore, infiltration of F4/80+iNOS+ M1 macrophages was enhanced by the dual therapy.

Conclusion

Anti-CD47 therapy could sensitize BCL tumors to anti-PD-L1 therapy in a CD8+ T-cell- and M1-macrophage-dependent manner by promoting cytotoxic lymphocyte infiltration, which may provide a potential strategy for BCL treatment by simultaneously targeting CD47 and PD-L1. Immune checkpoint inhibitors targeting PD-1/PD-L1 have become effective agents for cancer treatment. However, only a minority of patients benefit from this treatment in the clinic because of the limited response rate. Targeting CD47/SIRPα restores macrophage function and improves the response of antitumor immunity. Here, combination immunotherapy targeting CD47/SIRPα and PD-1/PD-L1 was investigated to increase the response rate and antitumor effect of PD-L1 monotherapy in B-cell lymphoma (BCL). This study broadens the application of the combination therapy and provided a promising strategy for B-cell lymphoma treatment by simultaneous targeting of PD-1/PD-L1 and CD47/SIRPα axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, B-CellNeoplasmsHumansCD47 AntigenCD8-Positive T-LymphocytesImmunotherapyMacrophagesB7-H1 Antigen

Stichwörter der Autor:innen

B-cell lymphomaCD47PD-L1combination therapyimmune checkpoint inhibitors

Substanzen

CD47 AntigenCD47 protein, humanB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, 201203, China.
  • Department of Cellular & Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.

ORCID-Profile: Dianwen Ju

Förderung

  • Scientific and Innovative Action Plan of Shanghai
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Shanghai Sailing Program

Zitieren

APA

Nan, Y., Zhang, X., Wang, S., Xu, C., Wang, Y., Han, L., Luan, J., Hu, X., Chen, W., Cao, Z., Zhu, Z., Zeng, X., Fan, J., Ye, L., Shi, X., & Ju, D. (2023). Targeting CD47 Enhanced the Antitumor Immunity of PD-L1 Blockade in B-Cell Lymphoma. Immunotherapy. https://doi.org/10.2217/imt-2022-0087

Vancouver

Nan Y, Zhang X, Wang S, Xu C, Wang Y, Han L, et al. Targeting CD47 Enhanced the Antitumor Immunity of PD-L1 Blockade in B-Cell Lymphoma. Immunotherapy. 2023. doi:10.2217/imt-2022-0087

BibTeX
@article{Nan2023,
  author = {Nan, Yanyang and Zhang, Xuyao and Wang, Shaofei and Xu, Caili and Wang, Yichen and Han, Lei and Luan, Jingyun and Hu, Xiaozhi and Chen, Wei and Cao, Zhonglian and Zhu, Zeguo and Zeng, Xian and Fan, Jiajun and Ye, Li and Shi, Xunlong and Ju, Dianwen},
  title = {Targeting CD47 Enhanced the Antitumor Immunity of PD-L1 Blockade in B-Cell Lymphoma},
  journal = {Immunotherapy},
  year = {2023},
  doi = {10.2217/imt-2022-0087}
}
Kostenlos starten →